Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Other Accumulated Expenses (2017 - 2022)

Denali Therapeutics has reported Other Accumulated Expenses over the past 6 years, most recently at $4.4 million for Q4 2022.

  • Quarterly Other Accumulated Expenses fell 91.75% to $4.4 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $4.4 million through Dec 2022, down 91.75% year-over-year, with the annual reading at $4.4 million for FY2022, 91.75% down from the prior year.
  • Other Accumulated Expenses was $4.4 million for Q4 2022 at Denali Therapeutics, down from $53.2 million in the prior quarter.
  • Over five years, Other Accumulated Expenses peaked at $53.2 million in Q4 2021 and troughed at $47000.0 in Q2 2018.
  • The 5-year median for Other Accumulated Expenses is $3.5 million (2019), against an average of $14.1 million.
  • Year-over-year, Other Accumulated Expenses soared 30801.59% in 2018 and then crashed 91.75% in 2022.
  • A 5-year view of Other Accumulated Expenses shows it stood at $19.5 million in 2018, then rose by 23.36% to $24.0 million in 2019, then skyrocketed by 96.31% to $47.1 million in 2020, then rose by 12.77% to $53.2 million in 2021, then crashed by 91.75% to $4.4 million in 2022.
  • Per Business Quant, the three most recent readings for DNLI's Other Accumulated Expenses are $4.4 million (Q4 2022), $53.2 million (Q4 2021), and $47.1 million (Q4 2020).